Current Report · Items 5.02, 7.01, 9.01 · 8-K

OptimizeRx Corporation

OPRXNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Filed Jun 24, 2025Accepted Jun 24, 2025, 7:45 AM EDTCIK 1448431Accession 0001213900-25-056908

Company context

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Current securities

OPRXNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective June 20, 2025, the Board increased the size of the Board to six (6) members and, upon the recommendation of the Board’s Nominating & Governance Committee, appointed the Company’s CEO Stephen Silvestro to serve as a director of the Company until the date of the Company’s 2026 annual meeting of stockholders and until his successor is elected and qualified, except in the event of his earlier death, resignation or removal.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 24, 2025, the Company issued a press release announcing changes to the Board described in Item 5.02 above. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. Exhibit Description Number ───────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated June 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

Filed exhibits (1)

EX-99.1 (by filename) ea024660201ex99-1_optimize.htm

EX-99.1 2 ea024660201ex99-1_optimize.htm PRESS RELEASE, DATED JUNE 24, 2025 Exhibit 99.1 OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors WALTHAM, MA - June 24, 2025 - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company’s CEO since March 2025, after serving as the interim CEO from January 2025. The appointment of Mr. Silvestro, with his knowledge of the Company and expertise in the industry, will enhance overall leadership and greatly contribute to the Company’s ability to execute its value creation plans and support key initiatives to deliver on its customer and shareholder roadmap. “The Board of Directors has been impressed with Steve’s leadership and the meaningful progress the Company has made since he stepped into the CEO role,” said Lynn Vos, Chairperson of OptimizeRx’…

Open exhibit ↗